Company intelligence / Profile preview

Starfish Medicines

Ann Arbor, Michigan, United States

Ownership: Private
Development stage: Other

Overview

Starfish Medicines is a biotechnology company focused on developing small molecule therapeutics that target RNA-protein interactions (RPIs). By leveraging a proprietary chemical biology platform, the company aims to modulate the function of RNA-binding proteins that are traditionally considered undruggable. Their primary focus is on oncology, where they seek to disrupt key pathways involved in cancer progression and resistance. The company's approach represents a novel way to target the transcriptome using traditional small molecule drug discovery methods.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Starfish Medicines.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Starfish Medicines.

Explore the full profile